Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments

Rokeya Akter1 · Md. Habibur Rahman2 · Tanima Bhattacharya3 · Deepak Kaushik4 · Vineet Mittal4 · Jatin Parashar4 · Kuldeep Kumar5 · Md. Tanvir Kabir6 · Priti Tagde7

Received: 21 May 2021 / Accepted: 25 September 2021 / Published online: 18 October 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
In the light of thousands of infections and deaths, the World Health Organization (WHO) has declared the outbreak of coronavirus disease (COVID-19) a worldwide pandemic. It has spread to about 22 million people worldwide, with a total of 0.45 million expiries, limiting the movement of most people worldwide in the last 6 months. However, COVID-19 became the foremost health, economic, and humanitarian challenge of the twenty-first century. Measures intended to curb the pandemic of COVID-19 included travel bans, lockdowns, and social distances through shelter orders, which will further stop human activities suddenly and eventually impact the world and the national economy. The viral disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After SARS-CoV-2 virus and Middle East respiratory syndrome (MERS)-related CoV, COVID-19 is the third most significant lethal disease to humans. According to WHO, COVID-19 mortality exceeded that of SARS and MERS since COVID-19 was declared an international public health emergency. Genetic sequencing has recently established that COVID-19 is close to SARS-CoV and bat coronavirus which has not yet been recognized as the key cause of this pandemic outbreak, its transmission, and human pathogen mechanism. This review focuses on a brief introduction of novel coronavirus pathogens, including coronavirus in humans and animals, its taxonomic classification, symptoms, pathogenicity, social impact, economic impact, and potential treatment therapy for COVID-19.

Keywords Emerging pathogens · Novel coronavirus · Social impact · Economy · Potential treatment · COVID-19

Introduction
In the mid of 1960s, coronaviruses were found to infect humans and livestock, including birds and mammals (Al Naggar et al. 2020). A novel coronavirus, a severe acute respiratory syndrome, coronavirus-2 (SARS-CoV-2), has been developed in recent times and has sparked a pandemic in several countries and territories, creating global health havoc (Rodriguez-Morales et al. 2020). Globally, according to the WHO, there were more than 21,867,420 confirmed cases of COVID-19 with over 4,507,837 death cases and 5,019,907,027 doses administered by 30 August 2021 (WHO Data August 2021). The pandemic of COVID-19 comes from the successful adaptation of SARS-CoV-2 to human transmission through zoonotic beta-coronaviruses (X. Li et al. 2020a, b). Travel bans, lockdowns, and social distance, also under “shelter in place” orders, are often used to curb this unprecedented challenge (Gu et al. 2020), which involve abrupt shifts in human activities and seriously affect the economy subsequently. Therefore, the social
and economic impacts of the COVID-19 pandemic are also expected to vary between countries. The countries or regions with longer social distances or greater reliance upon industries such as tourism or automotive industry that are most severely affected and face major challenges are expected to recover in China, where COVID-19 originated, earlier than Europe and North America.

It was understood that COVID-19 was involved in damage to multi-organ systems. The SARS-CoV-2 virus affects the lungs, heart, nerves, brain, vessels, kidneys, and skin (M. F. Hossain et al. 2020a, 2020b). Coronaviruses are one of the biggest groups of sense RNA viruses with spiky projections on their surface and have a broad, uncomplicated genome with a special, high degree of mutation and self-replicating recombination phenomenon. This virus will cross the boundary of this species and find a new host to live in and reproduce due to these special characteristics as examples of animal viruses that are of great importance in veterinary research methodology. Susan and Sonia have documented avian infectious bronchitis virus (IBV), bovine coronavirus (BCoV), and porcine transmissible gastroenteritis virus (TGEV) (Weiss et al. 2005). However, SARS-CoV, porcine epidemic diarrhea virus (PEDV), and Middle East respiratory syndrome coronavirus (MERS-CoV) are the best examples of CoV causing epidemic syndromes in animals with major economic losses, according to a study published in 2015 (Lau & Chan 2015).

The virus is widely adaptable to the host and is capable of causing serious illnesses in humans, rodents, dogs, cats, camels, pigs, chickens, and bats (Pal et al. 2020). BetaCoV conserved open reading frame 1a/b is less than 90% identity (Sharun et al. 2020a,b,c). In the internal environment, the infection was shown by dogs and cats with moderate to extreme symptoms (Mykytyn et al. 2020). Foodborne and zoonotic pathogens are an important threat in the poultry industry for eradication, elimination, and/or control (H. M. Hafez et al. 2020). With respect to novelty, SARS-CoV-2 differs from the two other zoonotic coronaviruses, SARS-CoV and MERS-CoV, introduced to humans earlier in the twenty-first century. A decade later, in 2012, MERS-CoV was also replicated as a zoonotic infection that contributed to a continuing outbreak and intermittent spread in the Arab Peninsula (Alluwaimi et al. 2020). SARS-CoV-2 is a new human CoV that, as of 5 August 2020, contributed to a worldwide current virus that claimed over 710,110 lives and infected over 18,895,712 individuals (of the International 2020). It is artistic with the potential to infect other animal species due to superior host adaptability compared to previous zoonotic coronaviruses (Tiwari et al. 2020). Chickens, ducks, and pigs, on the other hand, are not vulnerable to SARS-CoV-2 infection (Y. Zhao et al. 2020a,b,c). At present, health professionals worldwide are seeking to monitor more outbreaks of disease triggered by the new CoV (originally named 2019-nCoV). Pharmacokinetic models show that inhibiting SARS-CoV-2 in vitro, hydroxychloroquine sulfate is substantially superior (5 days prior) to chloroquine phosphate (Yao et al. 2020) and was demonstrated to be much less (40%) toxic than chloroquine in animals (McChesney 1983). In the current review, we focus on a brief introduction to novel coronavirus pathogens, including coronavirus in humans and animals, its taxonomic classification, symptoms, pathogenicity, social impact, economic impact, and potential treatment therapy for COVID-19.

**Symptoms**

The signs of COVID-19-infected persons are seen from 2 to 14 days, but this disease also prevails for 27 days. However, a group of Chinese researchers has shown the average incubation period is around 5.2 days (Pan et al. 2020). Time relies on the age and immune system of a patient. The patients were below the age of 70 years (W. Wang et al. 2020a,b,c,d). The most common signs of COVID-19 are fever, cough, and tiredness, while other signs are dry coughing, headache, hemoptysis, diarrhea, and lymphopenia (Carlos et al. 2020; Huang et al. 2020; Ren et al. 2020). Growing evidence indicates that environmental conditions might influence the current outbreak of COVID-19 (Hasana et al.). However, irregular characteristics, including RNAemia, acute syndrome of respiratory failure, acute heart injury, and the occurrence of ground-glass opacities leading to death, were seen via a chest CT scan showing pneumonia (Huang et al. 2020). BoCoVs have zoonotic potential in large animals as isolated from asymptomatic kids and have also been found to affect numerous domestic and wild ruminants, in which calf diarrhea in neonates, bloody diarrhea in adult cattle, and respiratory shipping fever are universal consequences in all age groups of cattle (Tiwari et al. 2020).

While CoVs have a prospective to be infectious from several days to several weeks on food or food packaging, the potency of infectivity decreases as time passes (Yekta et al. 2020). For their zoonotic origin, various investigations in China, Southeast Asia, and other constituencies targeting bats, wild and arrested pangolins, and other wildlife species will aid in better understanding (Hu et al. 2021). SARS-CoV-2 is endowed with the potential to infect other animal species due to superior host adaptability compared to previous zoonotic coronaviruses (Tiwari et al. 2020). It is believed that it has initiated from bats, just like SARS-CoV and MERS-CoV. They were spread to humans via civets and dromedary camels as intermediate hosts of SARS- and MERS-CoV, respectively (Park et al. 2020). It is considered that chickens, ducks, and pigs are not susceptible to this infection (Zhao et al. 2020a,b,c). In Southeast Asia, it was observed in bats and pangolins as SARS-CoV-2-related
viruses have earlier been identified in these creatures. Sequencing and PCR-based techniques offer more conclusive statistics; historical data revealed that serological studies can be superior and have a greater opportunity of victory for identification of virus origin because of the fact those virus-specific antibodies are retained longer than viral genetic material in diseased animals (Wacharapluesadee et al. 2021). In certain cases, some peripheral ground-glass opacity was found in subpleural portions of each of the lungs, which presumably caused systemic as well as localized immune responses contributing to increased inflammation (Lei et al. 2020) (Fig. 1). It should be noted that signs of COVID-19 are identical to early beta-coronavirus, such as fever, dry cough, and dyspnea as well as bilateral chest CT opacity in the ground-glass region (Huang et al. 2020). COVID-19 has shown some unusual clinical characteristics that show symptoms of the lower airways such as rhinorrhea, sneezing, and sore throat (Assiri et al. 2013; N. Lee et al. 2003). Some instances suggest that, after admission, the upper lung lobe has an infiltrate associated with increasing hypoxemia dyspnea (Phan et al. 2020).

**Pathogenesis and transmission of COVID-19**

The serious symptoms of COVID-19 are linked to a growing number and rate of deaths in an epidemic area of China in particular. The Chinese National Health Commission declared the first 17 deaths on 22 January 2020, and on 25 January 2020, it grew to 56 deaths (W. Wang et al. 2020a,b,c,d). Of 2684 registered cases of COVID-19, the death rate was about 2.84% as of 25 January 2020, and the average death age was about 75 (range of 48–89) years (W. Wang et al. 2020a,b,c,d). Patients with the COVID-19 count of 11,000 leucocytes/mm³ have been classified by their full blood cell count as patients with increased leucocyte count (K. Zhao et al. 2020a,b,c). The source of COVID-19 is SARS-CoV-2, a zoonosis that is possibly obtained by the ingestion of wild animals in foodstuffs or by the contact between rural and wildlife residents in those regions (Córdoba-Aguilar et al. 2020). Bats have been accused of evolving viruses since the advent of SARS-CoV and MERS-CoV. Recently, several studies have documented detecting pandemic coronaviruses (El Zowalaty & Jarhult 2020; Zhou et al. 2018). The clinical symptoms of nCOVID-19 are varied, such as cough, fever, tiredness, the radiographic indication of pneumonia, dyspnea, reduced or normal counts of leukocyte, and myalgia (Kabir et al. 2020). The SARS-CoV-2 transmission to mink caused the viral spread between farm animals and human spillover, resulting in mass ablation of mink to restrict the propagation of the virus. SARS-CoV-2 has been transmitted to mink, which has triggered viral spreading between animals and spilling into humans, leading to the mass exploitation of mink to reduce virus spread (Mykytyn et al. 2020). MERS-CoV has been documented as a newly developed zoonotic disease in dromedary camels (Alluwaimi et al. 2020). A genetic evolutionary study of SARS-CoV-2 has shown that two bat coronaviruses are genetically related to this virus (El Zowalaty & Jarhult, 2020). Because of numerous factors such as the flowering of trade and travel, variation in climate, quickly developing pathogens, population explosion, altering human habits and behaviors, intensive integrated animal farming, and others, the risk of evolving and re-emerging zoonoses has now improved worldwide (Bonilla-Aldana et al. 2020). Primary transmission occurs through close interaction between
dromedary camels and human beings (Fung et al. 2020; Kaur et al. 2021). Older and comorbid patients have an elevated risk of serious COVID-19 disease (Fung et al. 2020). In an attempt to avoid more public health risks associated with foodborne zoonotic diseases, SARS-CoV-2 supports a debate on permanently banning the eating of wildlife (Jacob et al. 2020). There was increasing interest in investigating the coronavirus in bats following the SARS outbreak in 2002 (Jacob et al. 2020). Apart from this, SARS-CoV-2 infection has been identified with animals from zoos such as tigers and lions and shows clinical symptoms including vomiting, diarrhea, dry cough, trouble breathing, and wheezing (Dhama et al. 2020a,b). The new MERS-CoV is enzootic (mostly Camelus dromedarius) in camels and contributes to a frequent human spill infection (Jo et al. 2020). Its zoonotic links and spillover and transmission to humans have been implicated in this infection as also reported with SARS and MERS (Dhama et al. 2020a,b).

Laboratory studies showed leucopenia (white blood cell count: 2.91×10⁹/L). Furthermore, a blood-C-reactive protein value more than the normal range (0–10 mg/L) was found to be 16.16 mg/L. Also, a high rate of sedimentation for erythrocytes and D-dimers was observed (Lei et al. 2020). Because of the high genetic diversity, the occurrence, and frequent recombination in a wide variety of species worldwide, CoV will reoccur from its reservoir to a new population and thus appear in humans (M. F. Hossain et al. 2020a,b). The key pathogenesis for COVID-19 infection, such as the respiratory systems, was severe pneumonia, RNAaemia, and acute cardiac damage combined with opacity in ground glass (Huang et al. 2020). In addition, the laboratory analyses of the plasma in relation to disease severity were also shown to be high concentration of other inflammatory cytokines including interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-10 (IL-10), and tumor necrosis factor-α (TNF-α) (Guo et al. 2020; Rothan et al. 2020; Huang et al. 2020). Studies in bats found the possible vector for human infections to be viruses originating in this genus. For example, there is a higher risk of horizontal (intra-species) transmission of these viruses because bats live in colonies. Further proof of bat to human indirect transfer comes from spike protein interactions with COVID-19 and the ACE2 receptor (W. Li et al. 2006). SARS-CoV and MERS-CoV are highly pathogenic coronavirus strains that have been found both in bat and human transmitting species (Docea et al. 2020). Interestingly, the first highly pathogenic SARS-CoV-1 strain of coronavirus has a poor genetic resemblance with other identified coronaviruses (Drosten et al. 2003). Three comparative experiments with pangolin strains have recently been performed. In the first (18 February 2020), a sequence of 85.5–91.4% compared COVID-19 to coronaviruses in trafficked pangolins (Lam et al. 2020), with the following papers showing a sequence of similarities of 90.23 and 91.02%, respectively, with pangolin coronaviruses (Xiao et al. 2020; Zhang et al. 2020). Although, SARS-CoV-2 has 96% genetic resemblance (whole genome) with coronavirus isolated in Chinese bat species, α-coronavirus strains that caused human diseases were originally described in the bats (P. Zhou et al. 2020a,b). Another main problem is, why China? China is the world’s third largest surface economy and most populated country. Its different soil features and climate support enormous biodiversity, which allows for virus transmission among animal populations. However, the close coexistence of animals and people and food traditions that involve several native animals such as wild animals (bats) result in high risk of vertical transmission across the food supply chain. Live-bird markets like those in China, near contact, and sometimes living in African rural areas with virtually no wild-environment barriers remain very common to humans and animals (Docea et al. 2020).

In another investigation, researchers demonstrated that ferrets, cats, and dogs could be infected experimentally with SARS-CoV-2 through the intranasal route (Tazerji et al. 2020). Mink such as ferrets belong to the Mustelidae family, and they have good susceptibility to SARS-CoV-2; therefore, mink can be utilized as an animal model for SARS-CoV-2 infection (Nadeem et al. 2020). It has been documented that efficient transmission among ferrets has been reported via direct contact with infectious ferrets and indirect airborne spread (Spiteri et al. 2020). The European Centre has reported for Disease Prevention and Control (ECDPC) that Europe owns about 2750 mink farms, producing greater than 27 million pelts each year. As we know, farmed minks are assembled in many groups in pens in wire cages placed with bedding that produces a greater amount of dust; therefore, there is boundless opening for transmission of infection among minks. Once the virus is introduced, this might ignore this spread because infected farms have been identified through serosurveys that suggest that disease might be mild, although upper and lower respiratory tract infection symptoms have also been reported (Oreshkova et al. 2020). In addition to this, it is also observed through the experience done from Denmark and the Netherlands that once the virus is introduced then it might be very problematic to halt transmission of the virus. There has been constant agricultural-to-farm transmission and numerous studies explore the methods of transmission between farms (Huo et al. 2020). Although it is also documented that adaptation to mink would lessen possibility of transmission among humans, a major concern is the accumulation of the virus in non-human reservoirs and from there viruses could be re-introduced, once spreading of SARS-CoV-2 in humans is suppressed or even immobile. In the Netherlands, a total of more than 2.7 million mink were registered on confirmation of SARS-CoV-2, which is 6.5-fold higher than total human cases. It is not clarified how this transmission of the virus has occurred between farms, and
the role of humans was considered in the transmission of this virus infection (Letko et al. 2020). These disclosed statistics have fostered discussions on the function of “herd immunity” in natural exposure to emergent tropical or maybe rural zoonoses. Notice that comparable threats have been reported with viruses that are not usually connected to highly biodiverse geographies or wild meat feeding. In particular, the 2012 MERS-CoV outbreak in the Middle East and Arab Peninsula has revealed that local and foreign city residents are not previously exposed to natural camelid hosts, who continue to have close ties with rural society (Azhar et al. 2014; Haagmans et al. 2014). As shown in COVID-19, the direct impact of zoonoses on individual health and indirect effects on healthcare systems emphasize the increased risk of human transmission in areas where there are blurred wildlife environments even among developed countries, despite past exposition and indeed immunity. The most common pathologic conditions underlying the disease are, i.e., pneumonia, mostly due to fever, tobacco, sore throat, exhaustion, headache, and shortness of breath. SARS-CoV-2 can lead to a severe immune reaction in the host body, leading to massive tissue damage in some cases. Interleukin-6 (IL-6), which triggered a series of inflammatory events, is one of the leading actors of this reaction. Viral pneumonia usually occurs bilaterally and affects primarily the lower lobes and is more serious in geriatric and comorbidity patients older than 70 years (Di Gennaro et al. 2020). Nevertheless, most children and young individuals suffering from SARS-CoV-2 have mild to moderate flu-like signs with an outstanding prognostic. In addition to the health conditions described above, several patients have complained of gastrointestinal issues including vomiting and diarrhea (Guo et al. 2020). SARS-CoV-2 has been conjectured to have initiated from bats and pangolins, although other species have been examined to establish some intermediate host. Its current detections in farms (mink), and domesticated (cats and dogs) and wild animals (tigers, pumas, and lions) have raised questions about the zoonotic origins of COVID-19 (Sharun et al. 2020a,b,c). In a subsequent SARS-CoV-2 natural infection investigation in farmed mink, a serological survey was executed among stray cats/feral cats found in the Netherlands around mink farms (Oreshkova et al. 2020; Sharun et al. 2020a,b,c). The illustrations of mink as a possible reservoir host of SARS-CoV-2 and transmission CoV strain are shown in Fig. 2. Viruses can come into the body via mucosa, especially nasal mucosa and larynx mucosa, pass through airways, reach the lungs, and quickly replicate (Li et al. 2020; 2021). While various transmission methods are available, the main route for the dissemination of the virus is through the propagation of breathing or sneezing which can also be done by asymptomatic persons (Jin et al. 2020; Morawska & Cao 2020). SARS-CoV-2 can also be transmitted via fecal–oral transmission because this virus has been found in patients’ stools and urines (Jin et al. 2020). If the virus has reached the body, angiotensin-converting enzymes 2 (ACE2) will potentially invade target tissues such as the liver, heart, kidney, and gastrointestinal tract (Jin et al. 2020).
Taxonomic classification and structure

Nidovirus order consists of the Coronaviridae family (SARS, PEDV), Arteriviridae (spinal and equine pathogens), and Roniviridae family (invertebrate virus) (Cowley et al. 2000). Figure 3 shows other common Nidovirales features. The key variances in the Nidovirus family are the number, size, and form of structural proteins that cause the virus structure’s morphologic and structural changes. Still under debate, coronavirus is in SARS-CoV (Goebel et al. 2004; Gorbalenya et al. 2004). The reverse transcript, phylogenetic replication, and nucleocapsid sequences of the coronavirus sequence of feral pigeons, graylag gulls, and mallards have been used for cellular receptors (Cavanagh et al. 2002; Jonassen et al. 2005). The current taxonomy of viruses users usually organize all diversity of viruses into a hierarchical structure in terms of the order, family, genus, and species (Alluwaimi et al. 2020). The coronavirus of about 80–125 nm in size is rounded, enveloped, and non-segmented. It contains positive sense RNA with a genome size of 30 kb and includes four structural proteins encoded within the viral genome’s 3′ end (Lee et al. 1991). The virus also includes membrane proteins, a small membrane protein, and a short N-terminal ectodomain, along with a cytoplasmic tail and a strongly lipophilic protein that stretches three times to the outer surface as shown in Fig. 4 (Delmas et al. 1990). Spike glycoprotein mediates the entry of coronaviruses into host cells (S protein). Overall, the SARS-CoV-2 S protein structure resembles that of the closely related SARS-CoV S protein. The S1 and S2 subunits remain non-covalently bound in a prefusion conformation. To identify various entry receptors, different types of coronaviruses use special domains in the S1 subunit (Wang et al. 2020a,b,c,d). Coronaviridae family members consist of large, enveloped RNA viruses with a single stranding. It is the most known RNA virus with genomes between 25 and 32 kb and virions with a diameter of 118–140 nm. Within the subfamily, Coronavirusae has four genera, the alpha-, beta-, gamma-, and deltacoronaviruses (Payne 2017). Both family members have the same special mRNA synthesis strategy in which the complex polymerase leaps from one region of the template into a distant region. Viruses are approximately spherical and notable for the large (S) spike glycoprotein, 16–21 nm from the envelope of the virus (Payne 2017). Table 1 offers a thorough classification of the coronavirus community with its CoV host, virus, disease, and cellular response. The structure of the human coronavirus causing respiratory syndrome is shown in Fig. 5.

Social impact

A combination of aspects like very high density, insufficient access to fundamental infrastructure services, and unstable living style makes it hard, if not difficult, to contain the spread of COVID-19 in slums via encouraging social distance and quarantine actions. These concerns have already been facts across various cities of Asia, South Africa, South America, and so on. Quarantine and social distancing could have a significant effect on the

Fig. 3 Characteristics of Nidovirales
psychological impact on the population’s health. Partitioning from dear ones, the loss of liberty, ambiguity over ailment status, and tediousness can, on occasion, create dramatic effects. Suicide has been reported, significant annoyance caused, and grievances fetch following the implementation of quarantine in earlier outbreaks (Zeidner et al. 2016). In reviewed investigations, economic loss because of quarantine produced severe socioeconomic distress and was reported to be a risk aspect for indications of psychological disorders, and both anger and anxiety continue months after quarantine. While quarantine and isolation are used to protect the physical health of individuals from infectious diseases, the mental health effects of these steps should also be taken into consideration for those with these limitations (Hossain et al. 2020a, b). Suicidal thoughts are also reported among people affected by COVID-19 (Hodžić et al. 2020). Lockdown severely affected schools’ and colleges’ regular schedule of education because all educational institutes were closed during this lockdown period and exams were also postponed. In addition to this, many research scholars put their research work on hold. Fear of infection, economic reduction, short

Table 1  Classification of host, virus, disease, and cellular response classes of coronavirus

| Group                  | Host category | Name of the virus                  | Cellular responses                  | Types of disease                                                                 | Reference                  |
|-----------------------|---------------|------------------------------------|-------------------------------------|---------------------------------------------------------------------------------|----------------------------|
| I (Animal pathogens)  | Cat           | Canine coronavirus, FeCoV, FIPV    | Canine and feline APN               | Respiratory, enteric and neurologic infection, and hepatitis                    | (Sood et al. 2020)         |
|                       | Pig           | TGEV, PRCoV                        | Porcine APN                         | Respiratory and enteric infection                                               | (Sood et al. 2020)         |
| II (Veterinary pathogens) | Cow          | 229E and NL-63 BCoV                | Human APN and ACE2                  | Respiratory infections                                                          | (Ijaz et al. 1985)         |
|                       |               |                                    | Neu5,9Ac2-containing moiety        | Enteric infection                                                               | (Sood et al. 2020)         |
|                       | Human         | OC43, HKU1, and SARS-CoV            | Neu5,9Ac2-containing moiety        | Respiratory infection, possibly enteric infection                               | (Saletti et al. 2020)      |
|                       | Pig           | Hemagglutinating encephalomyocarditis | Neu5,9Ac2-containing moiety        | Respiratory, enteric and neurologic infection, and hepatitis                    | (Sood et al. 2020)         |
|                       | Mouse         | MHV                                | Murine CEACAM1                      | Enteric and neurologic infection and hepatitis                                  | (Miura et al. 2004)        |
| III (Avian pathogens) | Chicken       | IBV                                | Not determined                      | Respiratory infection, hepatitis                                                | (Dai & Gao 2020)           |
|                       | Turkey        | Turkey coronavirus                 | Not determined                      | Respiratory and enteric infection                                               | (Bayram et al. 2020)       |
supplies, and stigmatization are the major issues that resulted in mental health problems during the COVID-19 era (Brooks et al. 2020). Suicidal cases were also identified among COVID-19-affected patients (Rogers et al. 2020). Another acute problem is the impact of COVID-19 on the psychological behavior of healthcare workers. Spoorthy et al. reported that healthcare employees across the globe had faced a significant degree of anxiety, stress, and insomnia during this pandemic era (Spoorthy et al. 2020). It can be summarized that the core of the COVID-19 pandemic is socioeconomic demographics. It significantly affects industrial and economic activities and ensures that post-COVID economic and social objectives are in stark contrast with the pre-COVID-19 timeline by introducing a full and minimal lockdown strategy.

According to data published on 20 May 2021 by Tencent (https://www.tencent.com/zh-cn/investors.html), in WeChat (WeiXin in Chinese), as a trending social media app for Chinese people’s daily work and life, every month there were > 1.2 billion active users globally. This app was not used for conducting commercial transactions, working, and learning but used for shopping, playing games, and communication. Additionally, it was also used to prevent infection with the COVID-19 virus and for close observation in China (Li et al. 2021).

Exercising at home may result in relief from stress, retaining fitness, and defending their life satisfaction. The latest study also revealed that people doing workouts regularly during this pandemic have the best mood (Brand et al. 2020). This virus hit almost all nations with wildly different levels due to differences in cultural norms and healthcare system, as well as mitigation events such as social distancing, resulting in closure of many public institutions (Okorie et al. 2021).

Economic impact

COVID-19 resulted in considerable chaos of the global economy, mainly in transport, the vacation industry, and global supply chain. The World Bank declared that gross domestic product worldwide contracted by 5.2% in 2020, the most significant decline in decades. The economic growth was diminished in all continents, namely the Middle East and North Africa (4.2%), East Asia and Pacific (0.5%), Sub-Saharan Africa (2.8%), South Asia (2.7%), Europe and Central Asia (4.7%), and Latin America (7.2%) (Pitoyo et al. 2021). After the highly integrated global capital outbreak, the influence of a new strain of coronavirus and mortality and morbidity has become evident. The global blocking was related to production interruptions as the global economy slowed down. The global supply chain, which contributes to a significant socioeconomic increase, was also interrupted. The findings show that the increasing number of lockdown days, fiscal arrangements, and travel constraints tremendously affected the degree of financial growth, and end, opening, minimal, and most notable stock expenses in large stock exchanges.

The impact of COVID-19 also affected the informal sector. The International Labour Organization (ILO) declared that more than 1.6 billion workers in informal sectors were
affected during this pandemic (ILO 2020a). Moreover, other concerns resulting from COVID-19 are the rise in unemployment and underemployment rates (ILO 2020b). More than 436 million informal businesses were highly affected economically throughout the pandemic, like manufacturing (111 million), housing and food (51 million), and other businesses (42 million) (ILO 2020a,b). The informal workers faced helplessness (Tim Forbil Institute and IGPA 2020). This pandemic resulted in skyrocketing food uncertainty in low-income continents, responsible for increment of susceptibility to this. The COVID-19 outbreak has severely impacted the economies worldwide. Varona et al. found that the leading economies dropped to an average of −5% in the year’s first quarter. The USA and the European Union economies are projected to drop −7.1% and −9.3%, respectively, for the year 2020 (Varona et al. 2021). The urban economy is decreased due to long-term economic shutdowns. Early research revealed that the outbreak had a considerable impact on city tax revenues, citizens’ income, tourism, unemployment, small and medium-sized businesses, urban food supply chains, and migrant workers (Sharifi et al. 2020). During the lockdown period, the traveling and transportation industries had fallen to almost zero. Economic institutes have relieved spur packages of > $6 trillion for solving this issue (Holmes et al. 2020). Agriculture, education, and healthcare sectors also have several negative impacts, but a drastic improvement in the air quality index of urban centers has been recorded during lockdowns (Kousi et al. 2021). The period of lockdown disrupted the mood of sports lovers also. Several sports events were canceled worldwide that not only affected the mood of sports lovers but also disrupted the financial status of sportspersons and organizations (Kousi et al. 2021). In one report on Greece, it was found that there was a decline in mobility trends in retail and recreation places (85%), parks (~70%), and transit stations (~80%). There was also a decline in movement near grocery and pharmacist shops (~45%), as well as working places (~55%) (Kousi et al. 2021).

On the other hand, the restriction on domestic development and higher spending of the money approach positively affected financial growth, although the increasing number of reported coronavirus cases had no significant impact on economic growth (Ozili et al. 2020). Global businesses, regardless of scale, have begun to face production and export cuts due to the further downturn in bounded transportation activities in confined countries. The tertiary sector has also had an impact on COVID-19. In addition to the impact on education for undergraduates, research into many non-COVID-related topics often impacts most strongly on the postgraduate research culture. In the UK, the national health research funding agency stops all non-COVID research so that qualified, usually academic, staff can go back to the frontline (Thornton 2020). Time, sales, and direct financial harm of the medical bears and related facilities are extra to the quantitative evaluation of the economic losses caused by COVID-19. India has been described as a tourism powerhouse and the world’s largest market in the Southern Asian economy. Today, it is the 8th largest nation to contribute to GDP (Sundaram et al. 2020). Although the COVID-19 pandemic is constantly spreading with little indication of containment as of 15 April 2020, it will probably have a very significant negative effect on economic growth in the region. The UN has warned of a coronavirus pandemic with a major adverse impact on the global economy, and India’s GDP growth is most importantly predicted to fall to 4.8% in the current economy (Neves et al. 2020). The decrease of social distance, travel constraints, and self-isolation reduced economic sectors around the world and caused the loss of a large number of educational institutions. In addition, various scientific conferences have been canceled or postponed. These conferences are important to scientific investigation in a wide range of fields which enable research to be distributed and provide collaborative and job search networking opportunities. Therefore, by taking into account the physical risk and social and physical distancing policies, the countrywide lockdown has enforced tremendous stress on the population below the poverty line. In the meantime, webinars played a significant role in providing people with recent information by increasing knowledge among them by claiming that they are in a pandemic situation at home.

**Potential treatments**

As a deadly new process and wreaking havoc have reached the COVID-19 pandemic, the world is seeking ways to slow the spread of new strains and discover viable drugs. It would promote the reduction of the burden on a nation’s healthcare system by limiting various critically ill people with COVID-19 and decreasing the length of the carriage of infection to reduce the transmission of the network (Colson et al. 2020). There is also a significant need for SARS-CoV-2 therapy. It is appalling that the FDA has not yet approved medicines for COVID-19; however, the coronavirus treatment acceleration program has created a single crisis program for potential therapies. It uses every method to transfer new drugs to patients as quickly as possible under the circumstances and at the same time testing for their utility or damage (FDA 2020). Currently, therapy is mainly symptomatic and organ support is given for critically ill individuals (Zumla et al. 2020). The use of old antiviral drugs will be a fascinating technique because of safety profiles, reactions, and phonology, and contact of medicines is remarkable (Colson et al. 2016). Here, we discuss a part of the essential medicinal products that can help combat COVID-19. Recent papers have revealed the inhibitory effect for the production of
SARS-CoV-2 in vitro by remdesivir and chloroquine (M. Wang et al., 2020). Thus, 20 clinical exams were carried out in many Chinese emergency clinics following the in vitro findings (Jie et al. 2020). The results show that chloroquine 500 mg was predominant twice a day for 10 days compared with control group therapy, as long as pneumonia, indicator duration, and viral liberty were decreased, all without extreme reactions (Gao et al. 2020). Similarly, it has been demonstrated that hydroxychloroquine (chloroquine analog) has an effect on in vitro SARS-CoV operation (Yao et al. 2020). A series of further in vitro preclinical studies indicate that both chloroquine and HIC have activity against SARS-CoV-2 despite an in vitro inquiry which suggests that HIC may be better than chloroquine and has a higher antiviral in vitro effect than chloroquine (Dong et al. 2020; Yao et al. 2020). The clinical benefit profile of hydroxychloroquine is better than that of chloroquine (when long-term use is required) and provides higher daily doses (Marmor et al. 2016). Both drugs are responsible for hindering large viral enzyme replication, such as DNA and RNA, and processes like glycosylation, assembly of viruses, the transport of new infection molecules, and discharge of infections. Some reports indicate that these drugs can lead to ACE2 receptor inhibition, surface acidifications of the membrane impeding virus fusion, and cytokine release immunomodulation (Ben-Zvi et al. 2012; Colson et al. 2020). Remdesivir is an antiviral agent with a wide variety of nucleosides (adenosine). Gilead Sciences developed it for Ebola infection in 2017. Remdesivir, for example, can repress SARS-CoV and MERS-CoV replication in in vitro studies (Rong et al. 2021; Agostini et al. 2018). Remdesivir represses movement using human CoV receptors of bat CoV, SARS-CoV, and MERS-CoV strains, which can replicate in human epithelial cells and function like intermediate channels. Remdesivir suggested prophylactic and remedial suitability for 2002 SARS-CoV (Agostini et al. 2018; Sheahan et al. 2017). Remdesivir was suggested as a possibility for treating COVID-19 patients (W. Liu et al. 2020a,b). Remdesivir has shown remarkable coronavirus activity and a great genetic barrier to resilience in preclinical trials (Agostini et al. 2018). The assessment of safety and effectiveness of reconstruction in hospitalized patients with mild or moderate respiratory disease COVID-19 will be performed by a randomized controlled, double-visual preliminary trial (Qu et al. 2020). Remdesivir treatment for a patient with COVID-19 was initiated intravenously on the 7th day. A total of 68% of patients were seen to benefit clinically with remdesivir when treated (Holshue et al. 2020). Remdesivir acts as a RNA-dependent polymerase inhibitor. Adenosine triphosphate is reportedly used to be inserted into the newer viral RNA chains. As no fast chain ends exist in RDV-TP (three additional nucleotides were linked after RDV-TP), the drug tends to resist viral exoribonuclease proofreading (Colson et al. 2016; Gordon et al. 2020; Warren et al. 2016; H. Zhao et al. 2020a,b,c). In the lopinavir- and ritonavir-treated patients, however, there was no difference between the length of viral shedding following clinical treatment improvement (Cao et al. 2020). These two medications have been found to bind with Mpro (key enzyme for the replication of virus) and to help prevent coronavirus action (W. Liu et al. 2020a,b; X. Liu et al. 2020a,b). Favipiravir, another commonly used antiviral medication popular in vitro for treating SARS-CoV-2 diseased RNA viruses, is clinically examined (Peking University 2020) (Shiraki et al. 2020). Favipiravir is a polymerase inhibitor of RNA, which suppresses RNA synthesis (Shiraki et al. 2020). Azithromycin and hydroxychloroquine were also used in a clinical trial to prevent bacterial polliination in COVID-19 patients (Gautret et al. 2020). At first, the possible value of azithromycin as additional therapy is apparent. Azithromycin was used as an adjunct therapy for MERS-CoV (Arabi et al. 2019). Teicoplanin, another glycopeptide for the treatment of bacterial infection used regularly, has been considered a SARS-CoV in vitro dynamic and combined with the rundown of particles that could have been used as a restraining agent against COVID-19 (Baron et al. 2020). This antibiotic has recently proven to be effective for various infections such as Ebola, flu virus, flavivirus, hepatitis C virus, HIV virus, and coronavirus, in particular, in staphylococcal infections (MERS-CoV and SARS-CoV) (Colson et al. 2016). The extended plasma junctions of inflammatory cytokines, such as TNF-α and IL-2, 7, and 10, have been seen in patients with COVID-19, in particular for ICU which indicated that a storm occurred (Huang et al. 2020). Based on these research findings, COVID-19 could prove effective by an inhibitor IL-6 monoclonal antibody, called tocilizumab. Of the 21 patients, 20 were recovered and released within 14 days of treatment after tocilizumab (Xu et al. 2020). Additional clinical feasibility knowledge for COVID-19 is evaluated (Zhao et al. 2020a,b,c). Tocilizumab prevents intercom passed IL-6 movement by binding IL-6 receivers both solvent and film-bound (Shetty et al. 2014). For COVID-19, other monoclonal IL-6 receptor inhibitors (sarilumab and siltuximab, namely) are suggested as they are responsible for cytokine discharge dysfunction that is a part of the severe cases in COVID-19 patients (Zhao et al. 2020a,b,c). The research was performed on 21 patients who were treated with siltuximab with COVID-19 pneumonia/ARDS (Gritti et al. 2020). In extreme COVID-19 patients, including IL-2, IL-4, IL-6, IL-7, IL-10, TNF-α, and IFN-γ, an elevated serum level of proinflammatory cytokines was recorded. Among these, a different intracellular signaling pathway regulated by Janus kinases (JAKs) is used by many cytokines (Luo et al. 2020). Another monoclonal antibody, leronlimab, responded by assessing cytokine tempests for possible treatment of COVID-19 to intensify the insensitive reaction (Muslim et al. 2020). The
use of COVID-19 convalescent plasma for treatment of patients with severe or immuno-life-threatening diseases is to be tested by clinical trials. The prevention of the disease is not predicted with COVID-19 recovery plasma. The plasma collected from those recovering from COVID-19 may have SARS-CoV-2 antibodies to clinical preliminaries in clinical patients (Caly et al. 2020). In patients administered convalescent plasma, rousing results were obtained. The FDA is also investigating the use of NSAIDs in patients suffering from COVID-19 (Caly et al. 2020). Worries have been suggested for the possible deterioration of COVID-19 symptoms, but no significant clinical evidence is available (Loutfy et al. 2003). The work of safe changes in COVID-19 care or prevention is unclear. Some improvements for both care and prophylaxis (for example zinc, nutrient C, and nutrient D) are under consideration in conjunction with other treatment approaches (Sood et al. 2020). Since COVID-19 disease is not licensed and investments in potential vaccine developments have to be made, it is ideal for everyone to unite their hands in combatting coronavirus by rehearsing self-cleanness and social distance. Remdesivir efficacy and safety is being tested in several clinical trials for COVID-19 therapy. The results were published in the latest clinical trial on COVID-19 by Gilead Sciences on remdesivir effectiveness (Grein et al. 2020). Ivermectin antiviral function is also found to be correlated with other pathways. Ivermectin has been reported to suppress pseudorabies virus replication by obstructing nuclear imports of UL42 (Sharun et al. 2020a,b,c). The efficacy of oseltamivir in treating SARS-CoV-2 infection is still being tested in many clinical trials. Oseltamivir is also used in some combinations such as with chloroquine and favipiravir, in clinical research (Rosa et al. 2020). The prodrug favipiravir first reaches the infected cells by endocytosis and is then converted by phosphorylation to the antiviral active ribofuranosyl phosphates (Furuta et al. 2017). Antiviral activity, however, is shown by selectively targeting conservative RNA-dependent RNA polymerase catalytic domain, interfering with the process of nucleotide addition during replication of viral RNA (Wu et al., 2020). Later, umifenovir was shown to have an in vitro antiviral effectiveness in the widespread virus strains including Ebola, human herpesvirus 8, hepatitis C virus, and arenavirus of Tacaribe (Pécheur et al. 2016). China is examining efficiency and safety of umifenovir for COVID-19 by executing two randomized and open-label trials (Wu et al. 2020). In this review, the utility of remdesivir was generally discussed. The sample size of this study was reasonably low for COVID-19 therapy; however, inefficiency and determining efficacy should be examined (Table 2) (Rahman et al. 2020a, 2020b). Immunotherapy, an effective way to treat infectious illnesses clinically, has been suggested (Cutino-Moguel et al. 2017). A new perspective on infectious disease control is the use of monoclonal antibodies. Monoclonal antibody is used to bind to a particular body material. This binding is very flexible and can imitate, block, or trigger change in precise mechanisms and provide an efficient treatment for diseases (Lu et al. 2020). Based on similarity among SARS-CoV-2 and SARS-CoV, multiple studies have shown that SARS monoclonal antiviral antibodies have been used in patients suffering from SARS-CoV-2 (W. Li et al. 2003). Dexamethasone, a broad-spectrum immunosuppressor agent, belongs to the synthetic corticosteroid class with greater activity and longer duration of action than cortisone (Huang et al. 2020; Theoharides & Conti 2020). It acts via different mechanisms of action; therefore, it can affect various systems of the body. Dexamethasone exhibits anti-inflammatory activity due to its ability to decrease the gene transcription of many pro-inflammatory cytokines, chemokines, and adhesion molecules (Rhen et al. 2005). Based on this fact, dexamethasone can be utilized to treat COVID-19 patients because of its property to inhibit the release of cytokines that further reduces their devastating effects. Therefore, this drug may be useful to curb the cytokine storm associated with COVID-19 (Huang et al. 2020). Moreover, it has been described by some studies that short-term use of dexamethasone reduced the severity of inflammation through inhibition of the cytokine storm and hyper-inflammatory phase in COVID-19 patients who developed pneumonia (Miga et al. 2020). These outcomes were further substantiated by a large randomized controlled trial (RECOVERY) that showed the promising effects of dexamethasone therapy on COVID-19 patients at the dose of 6 mg four times a day for 10 days. This RECOVERY trial reported that this treatment approach gave significant improvements in the patients with hypoxemia and who are under invasive and non-invasive respiratory support, but this study did not show any improvement sign in patients without hypoxemia (Verity et al. 2020; C. Wang et al. 2020a,b,c,d). On the other side, dexamethasone can also prevent the B-cell-mediated antibody production that further reduces the beneficial effects of T cells and eventually prevents the clearance of apoptotic cells mediated via macrophages that further increases the risk of secondary infections (Huang et al. 2020; Theoharides & Conti 2020). A national plan must be formulated and enforced internationally to contain the recent outbreak. The key lessons, however, are probably the fact that natural immunity is the first line of protection and that global health needs to be seen as a unit that cannot be easily dispelled. One of the most helpful immune therapies is the vaccine since it is able to facilitate defense against infectious diseases through the targeted path of the immune system (H. Hafez et al. 1999). A valuable, permanent vaccine and/or antiviral therapy for this will take time to grow (T. Rahman et al. 2020a,b). Human vaccines are vital for life-saving and well-being, and thus much more important than the invention of farm animal vaccines.
The global spread of SARS-CoV does not appear to threaten poultry production (Mykytyn et al. 2020). During the COVID-19 pandemic, the production of vaccines was highly regarded as the most powerful method for protecting human and animal health and eradicating health threats (H. M. Hafez et al. 2020). Investigations for the development of new vaccines and to monitor improvements in RNA and epidemiological diseases can continue to prevent risks of zoonotic disease (H. Hafez et al. 1999). CoV infection, however, is routinely monitored by vaccination on various domestic animals like cats, dogs, pigs, livestock, and poultry. The bovine coronavirus (BCoV) vaccines protect young calves from enteric and respiratory diseases (Alluwaimi et al. 2020).

For example, infectious bronchitis virus (IBV) was the first approved vaccine in chicks to prevent upper CoV infection in the respiratory tract (Alluwaimi et al. 2020). A majority of veterinary vaccines were developed to prevent shipping fever on young calves for CoVs, for example, canine enteric coronavirus (CECoV) infection in dogs, porcine epidemic diarrhea virus (PEDV), and transmissible gastroenteritis virus (TGEV) infections in pigs, and BCoV in cattle (Gerds et al. 2017). Recombinant vaccines have been promoted by the use of reverse genetics as a prevention strategy (Tizard 2020). Searching for a suitable vaccine by InovioPharmaceuticals and other firms, including CanSino Biologics, Sinovac Biotech Ltd., and Johnson&Johnson, for the SARS-CoV-2 mRNA-based vaccine (mRNA-1273) (NASDAQ: MRNA), is underway and the clinical trials are finalized. The clinical review involves 29 vaccine candidates and 138 are preclinical evaluations as of 13 August 2020 (Rabaan et al. 2020).

In addition, SARS-CoV-2 S-protein vaccine candidate is in the final step using mRNA vaccine technology (Rabaan et al. 2020). INOVIO Pharmaceuticals has developed and reportedly induces intradermal inoculation to induce immune cell activation through DNA plasmid–dependent vaccine aiming at SARS-CoV-2 protein (INO-4800) (Kim et al. 2020;
Rabaan et al. (2020). In comparison, recombinant vaccines based on DNA and mRNA are more available and quicker for clinical trials. DNA, chimeric viral, and membrane vesicle vaccines are valuable options (Shang et al. 2020).

Various efforts are ongoing for its treatment. Various vaccines have been developed but failed in clinical trials. But some of the vaccines got the approval of their treatment such as Covishield, Covaxin, Sputnik V, Moderna vaccine, Pfizer-BioNTech COVID-19 Vaccine, Johnson&Johnson’s, and Jab. Covishield and Covaxin are mostly vaccinated vaccines in India. India has also approved Johnson&Johnson’s single-dose vaccine for emergency usage. Jab is India’s second foreign vaccine to be granted emergency use authorization (Emergency approved vaccine 2021). Table 3 includes a list of vaccines approved for their emergency use.

The Sputnik V (uses adenoviruses) is also an approved vaccine that shuttles genetic material of SARS-CoV-2 into cells of vaccinated individuals. The mRNA-based Moderna vaccine spurs an immune response for at least half a year (Approved vaccine 2021). USFDA approved the first vaccine for COVID-19 called Pfizer-BioNTech and will now be commercially available as Comirnaty (koe-mir’-na-tee) for prevention of COVID-19 in persons 16 years and older (USFDA approved vaccine 2021).

**Conclusion**

In 2002, in Guangdong, China, the SARS-CoV-1 epidemic was a tragedy but in December 2019, in Wuhan, China, SARS-CoV-2 was a new coronavirus that triggered epidemics worldwide. This virus has spread so exponentially that more than hundreds of thousands of people worldwide have been infected. Although the source, nature, and transmission mechanism of coronaviruses are not yet clear, preventative action is recognized worldwide such as social distancing, hand washing, and hand sanitation. Researchers study this problem quickly and help people solve this pandemic. Doctors, intelligence agents at the border, military personnel, police officers, nurses, and local staff are all working hard to save the world from this epidemic. Quarantine and social distancing could substantially affect the psychological impact on the health of the population. Partitioning from dear ones, loss of liberty, ambiguity over ailment status, and tediousness can sometimes produce dramatic effects. Economic loss because of quarantine and severe socioeconomic distress were risk aspects for symptoms of psychological disorders, and both anger and anxiety continue months after quarantine. COVID-19 resulted in considerable chaos of the global economy, mainly in transport, the vacation industry, and global supply chain. The World Bank declared that gross domestic product worldwide contracted by 5.2% in 2020, the most significant decline in decades. Agriculture, education, healthcare, and informal sectors also have several negative impacts, but a drastic improvement in the air quality index of urban centers has been recorded during lockdowns. The global supply chain, which contributes to a big socioeconomic increase, was also interrupted.

To date, in large-scale clinical trials, most vaccine candidates have entered the final stages of vaccine safety and protection effectiveness, with very recent announcements by BioNTech/Pfizer and Moderna/NIAID claiming safety and very high levels of protection effectiveness for their leading candidates for mRNA vaccine. Covishield, Covaxin, and Sputnik V are the most used vaccines for vaccinations. India has also approved Johnson&Johnson’s single-dose vaccine for emergency usage. The Jab is the second foreign vaccine to be granted emergency use authorization in India. Different antiviral products have meanwhile been used primarily for short-term benefits, combined with azithromycin. Finally, this is a lesson for any possible pandemic like this to be learned based on this viral tragedy in terms of global and public health.

**Table 3** List of vaccines approved for their emergency use

| Vaccine Type         | Shot Type                  | Age group     | Adverse effects                                                                 |
|----------------------|----------------------------|---------------|---------------------------------------------------------------------------------|
| Pfizer-BioNTech mRNA| 2 shots, 21 days apart     | 16 and older  | Chills, pain, headache, tiredness, and swelling at the injection site           |
| Moderna mRNA         | 2 shots, 28 days apart     | Adults 18 and older | Chills, pain, headache, tiredness, and swelling at injection site            |
| Janssen Viral vector | Single shot                | Adults 18 and older | Fatigue, fever headache, injection site pain, or myalgia                         |
| Oxford-AstraZeneca   | 2 shots, 4–12 weeks apart  | Adults 18 and older | Tenderness, redness, pain, warmth, itching, swelling at the injection site         |
| Novavax Protein adjuvant | 2 shots, 3 weeks apart | 12–84 years old | Pain at the site of injection, fatigue, and fever                                |

**Author contribution** Idea: MHR and DK; Writing draft: RA; Review and editing: TB, VM, JP, KD, TK and PT. All authors read the final version of this manuscript and approved it for submission.

**Data availability** Not applicable.
Declarations

Ethics approval  Not applicable.

Consent to participate  Not applicable.

Consent to publish  Not applicable.

Competing interest  The authors declare no competing interests.

References

Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR, Jordan RJM (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proof-reading exoribonuclease. 9(2)

Al Naggar Y, Giesy JP, Abdel-Daim MM, Javed Ansari M, Al-Kahtani A, Elbek O, Köktürk N, Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar Arabi YM, Deeb AM, Al-Hameed F, Mandourah Y, Almekhlafi M, Al-Hajjar GA, Sindi AA, Al-Aithan AM, Al-Omari A, Shaltoub S, Mady A, Alraddadi B, Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Alraddadi R, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguière AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Hakeem RF, Makhdoom HQ, Zumla AI, Memish ZA (2013) Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease in Saudi Arabia: a descriptive study. 13(9), 752

Bonilla-Aldana DK, Dhama K, Patel SK, Pathak M, Yatoo R, Malik YS, Singh R, Sah R, Rabaan AA, Bonilla-Aldana DK, Rodriguez-Morales AJ (2020a) An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. 101755

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong Q, Xu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. 7, 382(19), 1787–1799

Carlos WG, Dela Cruz CS, Cao B, Pasnicky J, Samil S (2020) Novel Wuhan (2019-nCoV) coronavirus. P7-P8

Cavanagh D, Mawditt K, Welchman Dde B, Britton P, Gough RE (2002) Coronavirus diseases from pheasants (Phasianus colchicus) are genetically closely related to coronaviruses of domestic fowl (infectious bronchitis virus) and turkeys. 31(1), 81–93

Colson P, Raoult D (2016) Fighting viruses with antibiotics: an overlooked path. 48(4), 349

Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D (2020) Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. 105932(10.1016)

Córdoba-Aguilar A, Ibarra-Cerdeña CN, Castro-Arellano I, Suzan G (2020) Tackling zoonoses in a crowded world: lessons to be learned from the COVID-19 pandemic. 214, 105780

Cowley JA, Dinnock CM, Spann KM, Walker PJ (2000) Gill-associated virus of Penaeus monodon prawns: an invertebrate virus with ORF1a and ORF1b genes related to arteri-and coronaviruses. 81(6), 1473–1484

Cutino-Moguel MT, Eades C, Rezvani K, Armstrong-James D (2017) Immunotherapy for infectious diseases in haematological immunocompromise. 177(3), 348–356

Dai L, Gao GF (2020) Viral targets for vaccines against COVID-19. 1–10

Delmas B, Laude H (1990) Assembly of coronavirus spike protein into trimers and its role in epitope expression. 64(11), 5367–5375

Dhama K, Patel SK, Pathak M, Yatoo MI, Tiwari R, Malik YS, Singh R, Sah R, Rabaan AA, Bonilla-Aldana DK, Rodriguez-Morales AJ (2020a) An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. 101755

Dhama K, Patel SK, Pathak M, Yatoo MI, Malik YS, Sah R, Rabaan AA, Panwar PK, Singh KP, Michalak I, Chai-cumpa W, Martinez-Pulgarin DF, Bonilla-Aldana DK, Rodriguez-Morales AJ (2020b) SARS-CoV-2 jumping the species barrier: zooenotic lesions from SARS, MERS and recent advances to combat this pandemic virus. 101830

Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese E, Martínez-Pulgarín DF, Bonilla-Aldana DK, Rodríguez-Morales AJ (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. 7, 382(19), 1787–1799

Dong L, Hu S, Gao J (2020) Discovering drugs to treat coronavirus COVID-19: Can honeybee products help protect against the pandemic? 1527–1539

Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguière AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Müller S, Rickerts V, Stürmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW (2003)
ILO (2020b) COVID-19 crisis and the informal economy: immediate responses and policy challenges (ILO brief). https://www.ilo.org/global/topics/employment-promotion/informal-economy/publications/WCMS_743623/lang–en/index.htm. Accessed 12 Oct 2020

Jacob MCM, Feitosa IS, & Albuquerque UPJPHN (2020) Animal-based food systems are unsafe: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) fosters the debate on meat consumption. 23(1), 3250–3255

Jie Z, He H, Xi H, Zhi Z (2020) Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia 43(3):185–188

Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G (2020) Virolgy, epidemiology, pathogenesis, and control of COVID-19. 12(4), 372

Jo WK, de Oliveira-Filho EF, Rasche A, Greenwood AD, Osterrieder K, Drexler KJ (2020) Potential zoonotic sources of SARS-CoV-2 infections. 68(4), 1824–1834

Jonassen CM, Kofstad T, Larsen IL, Lövland A, Handeland K, Follstad A, Lillemo A (2015) Molecular identification and characteriztion of novel coronaviruses infecting graylag geese (Anser anser), feral pigeons (Columbia livia) and mallards (Anas platyrhynchos). 86(6), 1597–1607

Kabir MT, Uddin MS, Hossain MF, Abdulhakim JA, Alam MA, Ashraf GM, Bungau SG, Bin-Jumah MN, Abdel-DaimMM, Aleya L (2020) nCOVID-19 pandemic: from molecular pathogenesis to potential investigational therapeutics.10(8), 616

Kaur A, Bhalla V, Salahuddin M, Rahman SO, Pottoo FH (2021) COVID-19 infection: epidemiology, virology, clinical features, diagnosis and pharmacological treatment. 11

Kim YC, Dema B, Reyes-Sandoval A (2020) COVID-19 vaccines: breaking record times to first-in-human trials. 5(1), 1–3

Kousi T, Mitsi LC, Simos J (2021) The Early stage of COVID-19 outbreak in Greece: a review of the national response and the socioeconomic impact. 18(1), 322

Lam TT, Jia N, Zhang YW, Shum MH, Jiang JF, Zhu HC, Tong YG, Shi YX, Ni XB, Liao YS, Li WJ, Jiang BG, WeiW, Yuan TT, Zheng K, Cui KX, Li XM, Li P, Qi X, Cheung YW, Li LF, Sun FF, Qin S, Huang JC, Leung GM, Holmes EC, Hu YL, Guan Y, Cao WC (2020) Identification of 2019-nCoV related coronaviruses in Malaysianpoulings in southern China. 583(7815), 282–285

Lau SK, Chan JF (2015) Coronavirus: Emerging and re-emerging pathogens in humans and animals. 12, 209

Lee HJ, Shieh CK, Gorbalenya AE, Koonin EV, La Monica N, Lillehaug A (2005) Molecular identification and characterization of SARS-CoV. 865(7823), 79–84

Lee NS, Wang XJ (2020) Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. 47(2), 119

Loutfy MR, Blatt LM, Siminovich KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, LaMere EA, Chang M, Kain KC, Farcas GA, Ferguson P,Latchford M, Levy G, Dennis J, Lai EK, Fish EN (2003) Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. 290(24), 3222–3228

Luo RM, Hwang YC, Liu JJ, Lee CC, Tsai HZ, Li JH, Wu HC (2020) Development of therapeutic antibodies for the treatment of diseases. 27(1), 1–30

Luo W, Li YX, Jiang L, Chen Q, Wang T, Ye DW (2020) Targeting JAK-STAT signaling to control cytokine release in COVID-19. 41(8), 531–543

Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). 123(6), 1386–1394

McChesney EW (1983) Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. 75(1), 11–18

Miga KH, Koren S, Rhee A, Vollger MR, Gershman A, Brikzadek A, Brooks S, Howe E, Porubsky D, Logsdon GA, Schneider VA, Potapova T, Wood J, Chow W, Armstrong J, Fredrickson J, Pak E, Tigi K, Kozmikzi M, Markovic C, Maduro V, Dutra A, Bouffard GG, Chang AM, Hansen NF, Willert AB, Thibaud-Nissen F, Schmitt AD, Belton JM, Selvaraj S, Dennis MY, Soto DC, Sahasrabudhe R, Kay A, Quick J, Loman NJ, Holmes N, Loose M, Suri R, Risques RA, Graves Lindsay TA, Fulton R, Hall I, Paten B, Howe K, Timp W, Young A, Mullikin JC, Pevzner PA, Gerton JL, Sullivan BA, Eichler EE, Phillippy AM (2020) Telomere-to-telomere assembly of a complete human X chromosome. 385(7823), 79–84

Miura HS, Nakagaki K, Taguchi F (2004) N-terminal domain of the murine coronavirus receptor CEACAM1 is responsible for fusogenic activation and conformational changes of the spike protein. 78(1), 216–223

Morawska L, Cao J (2020) Airborne transmission of SARS-CoV-2: the world should face the reality. 105730

Muslim S, Nasrin N, Alotaibi FO, Prasad G, Singh SK, Alam I, Mustafa G (2020) Treatment options available for COVID-19 and an analysis on possible role of combination of rACE2, angiotensin (1-7) and angiotensin (1-9) as effectve therapeutic measure. 22, 1–6

Mykytyn AZ, Lamers MM, Okba NMA, Breugem TI, Schipper D, van Doel PB, van Run P, van Amerongen G, de Waal L, Koopman MPG, Stittelaar KJ, van den Brand JMA, Haagmans BL (2020) Susceptibility of rabbits to SARS-CoV-2. 1

Nadeem S, Abbas N, Elmasry Y, Malik MY (2020) Numerical analysis of water based CNTs flow of micropolar fluid through rotating frame. 186, 105194

Neves R, Cho H, Zhang J (2020) State of the nation: customizing energy and finances for geothermal technology in the United States residential sector. 110463

of the International- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020) The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. 5(4), 536
Castell M, Pozo F, Maksyutov RA, Martin C, Van Ranst M, Bossuyt N, Siira L, Sane J, Tegmark-Wisell K, Palmérus M, Broberg EK, Éauté J, Jorgensen P, Bundle N, Pereyaslav D, Adlhioch C, Pukkila J, Pebody R, Olsen S, Ciancio BC (2020) First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region. 24 January to 21 February 2020. 25(9), 2000178

Sporrothy MS, Pratapa SK, Mahant S (2020) Mental health problems faced by healthcare workers due to the COVID-19 pandemic – A review. 51, 102119

Sundaram S, Nair SS, Jaganmohan D, Unnikrishnan G, Nair MJMSJ (2020) Relapsing lamboasotic Myeloradulitis: an Unusual Presentation of MOG Antibody Disease. 26(4):509–511

Tazerji SS, Magalhães Duarte P, Rahimi P, Shahabinejad F, Dhakal S, Singh Malik Y, Shehata AA, Lama J, Klein J, Safdar M, Rahman MT, Filipiak KJ, Rodríguez-Morales AJ, Subar MA, Kabir F, Vazir B, Mboera L, Coparole M, Islam MS, Amuusi JH, Gharieb R, Roncada P, Musaad S, Tiloca B, Khoobi MK, Taghipour A, Sait A, Subbaram K, Jahandideh A, Mortazavi P, Abedini MA, Hokey DA, Hogan U, Shaheen MNF, Elaswad A, Elhaig MM, Fawzy M (2020) Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review. 18(1), 1–11

Tencent (2021) https://www.tencent.com/zh-cn/investors.html

Theoharides TC, Conti P (2020) Dexamethasone for COVID-19? Not so fast. 34(3), 10.23012/Ami-2020-34-3-1592

Thornton J (2020) Clinical trials suspended in UK to prioritise theoharides TC, Conti P (2020) Dexamethasone for COVID-19? Not so fast. 34(3), 10.23012/Ami-2020-34-3-1592

Wacharapluesadee S, Tan CW, Maneeorn P, Duengkae P, Zhu F, Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Varona L, Gonzales JR (2021) Dynamics of the impact of COVID-19 pandemic. 20(6), 669–677

Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM (2020c) SARS-CoV-2: structure, biology, and structure-based therapeutics. 10, 58726

Wang W, Tang J, Wei F (2020d) Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan. China 92(4):441–447

Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JSE, Nagle ER, Kugelman JR, Palacios G, Doerfler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe D, Babusdi D, Park Y, Stray KM, Traencheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fears R, Swanmanthan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavar S (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. 531(7594), 381–385

Weiss SR, Navas-Martin S (2005) Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. 69(4), 635–664

WHO Data August (2021) https://www.who.int/emergencies/diseases/novel-coronavirus-2019/ad groupsurvey?=adg oursurvey&gclid=Cj0KCQKWyprwPBLDrAvsAF1_ BU3dirdzhyh7bNeg-HEWPYXkpjCMX6U9bTEnmrvrVgZtXSxW6yQkUqAII-AEALw_wcB. Accessed 15 Aug 2021

Xiao H, Zhang Y, Kong D, Li S, Yang N (2020) The effects of social support on sleep quality of medical staff treating patients with coronavirus disease 2019 (COVID-19) in January and February 2020 in China. 26, e923549–923549

Yao X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H (2020) Effective treatment of severe COVID-19 patients with tocilizumab. 117(20), 10970–10975

Xiao H, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM (2020c) SARS-CoV-2: structure, biology, and structure-based therapeutics. 10, 58726

Yang X, Ye F, Zhang M, Cui H, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 92(4), 732–739

Yekta R, Vahid-Dastjerdi L, Norouzbeigi S, Mortazavian AM (2020) The effects of social support on sleep quality of medical staff treating patients with coronavirus disease 2019 (COVID-19) in January and February 2020 in China. 26, e923549–923549

Yi J, Wang G, Liu T, Shao Y, Ao S, Zhang Z, Li L, Xiong J, Zhang J, Yang X, Liu S, Wang X, Liao L, Wang J, Pan J, Zhang H, Chen X, Li F, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H (2020) Effective treatment of severe COVID-19 patients with tocilizumab. 117(20), 10970–10975

Yao X, Ye F, Zhang M, Cui H, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 92(4), 732–739

Yekta R, Vahid-Dastjerdi L, Norouzbeigi S, Mortazavian AM (2020) The effects of social support on sleep quality of medical staff treating patients with coronavirus disease 2019 (COVID-19) in January and February 2020 in China. 26, e923549–923549

Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM (2020c) SARS-CoV-2: structure, biology, and structure-based therapeutics. 10, 58726

Zhao W, Tang J, Wei F (2020d) Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan. China 92(4):441–447

Zhao X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H (2020) Effective treatment of severe COVID-19 patients with tocilizumab. 117(20), 10970–10975

Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM (2020c) SARS-CoV-2: structure, biology, and structure-based therapeutics. 10, 58726

Zhao X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H (2020) Effective treatment of severe COVID-19 patients with tocilizumab. 117(20), 10970–10975

Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, Chen G, Wang K, Yu J, Wu Z, Chen X, Wang G (2020a) Tocilizumabcombined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. 133, 110825

Zhao K, Li R, Wu X, Zhao Y, Wang T, Zheng Z, Zeng S, Ding X, Nie H (2020b) Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis. 39(12), 2279–2287
Zhao Y, Wang J, Kuang D, Xu J, Yang M, Ma C, Zhao S, Li J, Long H, Ding K, Gao J, Liu J, Wang H, Li H, Yang Y, Yu W, Yang J, Zheng Y, Wu D, Lu S, Liu H, Peng X (2020c) Susceptibility of tree shrew to SARS-CoV-2 infection. 10(1), 1–9

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020a) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. 395(10229), 1054–1062

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL (2020b) A pneumonia outbreak associated with a new coronavirus of probable bat origin. 579(7798), 270–273

Zhou P, Fan H, Lan T, Yang XL, Shi WF, Zhang W, Zhu Y, Zhang YW, Xie QM, Mani S, Zheng XS, Li B, Li JM, Guo H, Pei GQ, An XP, Chen JW, Zhou L, Mai KJ, Wu ZX, Li D, Anderson DE, Zhang LB, Li SY, Mi ZQ, He TT, Cong F, Guo PJ, Huang R, Luo Y, Liu XL, Chen J, Huang Y, Sun Q, Zhang XL, Wang YY, Xing SZ, Chen YS, Sun Y, Li J, Daszak P, Wang LF, Shi ZL, Tong YG, Ma JY (2018) Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin. 556(7700), 255–258

Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M (2020) Reducing mortality from 2019-nCoV: host-directed therapies should be an option. 395(10224), e35–e36

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.